Akeso, Inc. (HKG:9926)
Hong Kong · Delayed Price · Currency is HKD 93.95
+0.75 (0.80%)
Jul 31, 2026, 4:08 PM HKT
Akeso Employees
Akeso had 3,761 employees as of December 31, 2025. The number of employees increased by 726 or 23.92% compared to the previous year.
Employees
3,761
Change
726
Growth
23.92%
Revenue / Employee
904.30K HKD
Profits / Employee
-329.32K HKD
Market Cap
86.54B
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 3,761 | 726 | 23.92% |
| Jun 30, 2025 | 3,529 | - | - |
| Dec 31, 2024 | 3,035 | 257 | 9.25% |
| Dec 31, 2023 | 2,778 | 437 | 18.67% |
| Dec 31, 2022 | 2,341 | 476 | 25.52% |
| Dec 31, 2021 | 1,865 | 1,119 | 150.00% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Sino Biopharmaceutical | 21,435 |
| WuXi Biologics | 13,252 |
| Innovent Biologics | 7,502 |
| Genscript Biotech | 6,165 |
| 3SBio | 6,109 |
| Shanghai Henlius Biotech | 3,762 |
| RemeGen | 3,048 |
| Shanghai Junshi Biosciences | 2,903 |
Akeso News
- 12 days ago - Akeso Doses First Patient In Phase II Study Of Novel Bispecific ADC In Advanced NSCLC - Nasdaq
- 18 days ago - Phase II Trial of Cadonilimab(PD-1/CTLA-4) Combination Regimen Launches in the United States for Perioperative Treatment of Gastric Cancer - PRNewsWire
- 6 weeks ago - Ligufalimab (CD47)-Based Combination Achieves Deep Responses and Survival Benefit in Frontline AML: Phase II Results Presented in Oral Session at EHA 2026 - PRNewsWire
- 7 weeks ago - Akeso's Gumokimab (AK111, Anti-IL-17) Approved by NMPA for Moderate-to-Severe Plaque Psoriasis, Bolstering Its Autoimmune Disease Portfolio - PRNewsWire
- 2 months ago - An experimental lung-cancer drug could replace Keytruda one day. But investors aren't wowed. - Market Watch
- 2 months ago - Summit rises after lung cancer drug trial shows 15% higher survival rate than rival's - Reuters
- 2 months ago - Akeso lung cancer drug helps patients live 15% longer than immunotherapy in China trial - Reuters
- 2 months ago - A hotly debated lung cancer drug cut the risk of death by 34% in a late-stage trial in China - CNBC